Cost - effectiveness analysis of the antiplatelet treatment administered on ischemic stroke patients using goal programming approach

• Published in: AIP conference proceedings Vol. 1613; no. 1
• Main Authors: Rajendran Rasvini, Zainuddin Zaitul Marlizawati, Idris Badrisyah
• Format: Conference Proceeding
• Language: English
• Published: Melville American Institute of Physics 12.09.2014
• Subjects: Cost analysis; Goal programming; Patients; Stroke
• ISSN: 0094-243X; 1551-7616
• DOI: 10.1063/1.4894333

There are numerous ways to prevent or treat ischemic stroke and each of these competing alternatives is associated with a different effectiveness and a cost. In circumstances where health funds are budgeted and thus fixed, cost-effectiveness analysis (CEA) can provide information on how to comprehend the largest health gains with that limited fund as CEA is used to compare different strategies for preventing or treating a single disease. The most common medications for ischemic stroke are the anti-platelet drugs. While some drugs are more effective than others, they are also more expensive. This paper will thus assess the CEA of anti-platelet drug available for ischemic stroke patients using goal programming (GP) approach subject to in-patients days and patients' quality-of-life. GP presents a way of striving towards several objectives simultaneously whereby in this case we will consider minimizing the cost and maximizing the effectiveness.